Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the efficacy and safety of continuous intravenous
administration of low dose iloprost versus placebo for 72-hours, in up to a total of 380
patients with septic shock suffering from organ failure.
The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as
it is anticipated to deactivate the endothelium and restore vascular integrity in septic
shock patients suffering from organ failure caused by endothelial breakdown, ultimately
improving survival.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jakob Stensballe, MD, PhD
Collaborators:
Independent Research Fund Denmark Innovation Fund Denmark